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Amiodarone-Associated Optic Neuropathy
Abstract
A 72-year old male presented symptomatic for unilateral inferior visu-
al field loss, but was found to have bilateral optic neuropathy. Clinical 
features, an extended minimally symptomatic course and a temporal 
relationship to amiodarone use implicated amiodarone-associated op-
tic neuropathy. Serial ancillary testing analyses provided insight into 
this entity’s natural course. This patient developed the greatest retinal 
nerve fiber layer thinning in the inferior quadrant; this may correlate 
with anatomically larger-diameter axons, supporting a previous publi-
cation which suggested that larger-diameter optic nerve axons are more 
susceptible to amiodarone-induced lipidosis. While rare, amiodarone-
associated optic neuropathy may develop and cause permanent loss of 
visual function.
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INTRODUCTION
Amiodarone-associated optic neuropathy has been reported in 1.79% of amiodarone users.1 However, the most 
recent critical review of this entity, in 2012, identified fewer than 300 cases reported, with only 59 published, 
and only a small number of case reports have been published since.2 This case adds to the small body of litera-
ture which details the course of amiodarone-associated optic neuropathy, supports its diagnosis as a distinct 
clinical entity, and provides comprehensive serial photographs, optical coherence tomography and the results 
of visual field analyses. These findings provide insight into the natural course of amiodarone-associated optic 
neuropathy. 
CASE REPORT 
A 72 year-old white male presented as a new patient reporting a dark arc-shaped scotoma in the bottom portion of 
the right eye’s vision. He had initially reported this to his clinical pharmacist about 2 months previously. He denied 
headaches, jaw claudication, temporal tenderness, transient visual obscurations, nausea, vomiting, fever, malaise 
and diplopia. His last eye exam had been 5 years previously and was reported as unremarkable. 
His medical history included diverticulitis, esophageal reflux, colonic polyps, herpes simplex 1, degenerative 
joint disease, congestive heart failure and atrial fibrillation. Six months previously, the patient had been hospi-
talized for progressive shortness of breath with left leg edema due to atrial fibrillation with rapid ventricular 
response. He was given an intravenous loading dose of amiodarone for 24 hours, then 400 mg twice per day for 
10 days, and was discharged on 200 mg daily. He was also taking bumetanidine 3 mg daily, metoprolol 37.5 mg 
daily, omeprazole 20 mg daily, polyethylene glycol powder daily and warfarin (3 mg on Mondays, Wednesdays 
and Fridays and 2 mg on Tuesdays, Thursdays, Saturdays and Sundays). His social and family history were 
non-contributory. 
His best corrected acuity was 20/40 in the right eye and 20/25 in the left eye. He had a mild right afferent pupil-
lary defect. Other initial findings and anterior segment exam were non-contributory. On dilated fundus exam, 
the right eye had a cup-to-disc ratio of 0.15/0.15 with a sector of neuroretinal rim pallor superotemporally, 
and the inferior half of the disc was edematous. There were disc hemorrhages inferonasally and superonasally 
(Figure 1A). The left eye had no appreciable cupping with a diffusely edematous disc and disc hemorrhages 
nasally and temporally (Figure 1B). His blood pressure in clinic was 116/75 with a regular pulse rate of 71 beats 
per minute. Visual field showed a moderate inferior arcuate defect with a few depressed superior edge points 
in the right eye, and superior and inferior arcuate defects in the left eye (Figures 2 and 3). Optical coherence 
tomography retinal nerve fiber layer analysis using a Cirrus device (Carl Zeiss, Oberkochen, Germany) showed 
superior thinning in the right eye, with an overall average thickness of 70 μm. The left optic disc’s neuroretinal 
rim and retinal nerve fiber layer were grossly elevated, with an average thickness of 154 μm. 
The main differential diagnoses at that time included papilledema; bilateral versus sequential anterior ischemic 
optic neuropathy, either arteritic or non-arteritic; and amiodarone-associated optic neuropathy. 
He was initially evaluated emergently by computed tomography without contrast, and then later evaluated by 
magnetic resonance imaging of the brain and orbits, both with and without contrast, and by magnetic reso-
nance venography. The results were normal with no evidence of a space-occupying lesion, or secondary radio-
logic signs of increased intracranial pressure or dural venous sinus thrombosis. The patient’s complete blood 
count was normal, platelets were normal (256 x103/μL, reference range 130-400 x103/μL), C-reactive protein 
was elevated (1.305 mg/dL, reference range 0-0.748 mg/dL) and the Westergren erythrocyte sedimentation 
rate was mildly elevated (23 mm/hour, reference range 0-15 mm/hour), though the clinical picture was not 
suggestive of giant cell arteritis. At that time, the most likely differential diagnoses became bilateral versus 
sequential non-arteritic anterior ischemic optic neuropathy and amiodarone-induced optic neuropathy. 
The patient was followed-up at 4 weeks, with no changes in his health or medication history in the interim; his 
visual symptomatology was stable in the right eye, and he remained asymptomatic in the left eye. He again denied 
headaches, temporal tenderness and jaw claudication. His vision was pinholed to 20/50 right eye, 20/30- left eye. 
Dilated fundus exam of the right eye still showed an edematous inferior disc margin and superotemporal pallor, 
but the disc hemorrhage had resolved (Figure 1C). The left optic nerve was still diffusely edematous with a disc 
hemorrhage temporally (Figure 1D). His visual field indicated a deeper inferior arcuate defect, with worsened 
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sensitivity of several points and worsened mean and pattern standard deviation, with a few scattered superonasal 
rim defects in the right eye (Figure 2); the left eye showed an incomplete inferior arcuate defect with a cluster of 
defects superonasally, which was slightly improved in both hemifields (Figure 3). The retinal nerve fiber layer by 
optical coherence tomography was stable in the right eye, and still grossly elevated, but with an average thickness 
of -31 μm (123 μm) in the left eye compared to previously. 
Figure 1: Serial optic nerve photographs of the right (top panel) and left (bottom panel) eyes. Initial presentation: (A) 
right eye showing superotemporal pallor, inferior disc edema, and inferonasal and superonasal hemorrhages; (B) left eye 
showing diffuse disc edema and nasal and temporal hemorrhages. At 1 month: (C) right eye showing superotemporal 
pallor, inferior disc edema with the resolution of disc hemorrhages but an intraretinal hemorrhage superior to the disc; 
(D) left eye showing diffuse edema and a disc hemorrhage nasally. At 2 months: (E) right eye showing superotemporal 
pallor, inferior edema; (F) left eye showing diffuse disc edema and a disc hemorrhage nasally. At 2.5 months: (G) right eye 
showing stable superotemporal pallor and inferior edema; (H) left eye showing diffuse disc edema without hemorrhaging. 
At 6 months: (I) right eye showing superotemporal pallor and resolution of the inferior disc edema; (J) left eye with disc 
edema clinically resolved. At 8 months: (K) right and (L) left eyes are clinically stable. At 18 months: (M) right and (N) 
left eyes remain clinically stable.   
After consultation with the patient’s cardiologist and clinical pharmacist, given that the patient’s electrocardiogram 
readings since amiodarone initiation had shown normal sinus rhythm and the patient was anticoagulated with war-
farin, the choice was made to discontinue amiodarone and follow-up closely with cardiology. 
Over the subsequent weeks and months, the patient was routinely followed-up with serial dilated fundus 
exams, photographs, visual field exams and optical coherence tomography. Over that time, laboratory test-
ing of the erythrocyte sedimentation rate and C-reactive protein down-trended, complete blood counts and 
platelets remained normal, hemoglobin A1c was normal at 5.9%, and rapid plasma reagin syphilis screening 
was non-reactive. His acuity ultimately stabilized at 20/30 in the right eye, which represented an improve-
ment of about 1 line of Snellen acuity, and 20/25 in the left eye, which was roughly stable compared to the 
initial presentation. 
The optic disc edema in both eyes resolved clinically at 6 months, leaving associated atrophy that correspond-
ed to retinal nerve fiber layer thinning on optical coherence tomography. Progression analysis of the retinal 
nerve fiber layer clearly indicated stability in the area where pallor had been evident on presentation (supe-
rotemporally) in the right eye, but showed progressive thinning inferiorly as the edema resolved. Similarly, 
diffuse progressive retinal nerve fiber layer thinning over the clinical course was visualized in the left eye. 
Though the disc edema had resolved clinically at 6 months in both eyes, additional retinal nerve fiber layer 
thinning in the left eye was evident at 8 months on optical coherence tomography (Figures 4 and 5, Table 1). 
Visual fields ultimately stayed relatively stable in both eyes (Figures 2 and 3, Table 2). His clinical evaluation at 
18 months was stable relative to the 8-month evaluation (Figure 1). Amiodarone-associated optic neuropathy 
was strongly implicated in this case. 
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Figure 2: Serial visual fields of the right eye. Visual field of the right eye at ( from top down) the initial presentation, and after 
1, 2, 4 and 8 months showing an inferior arcuate defect and a small cluster of superocentral edge defects, which remained 
relatively stable and permanent throughout the clinical course.
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Figure 3: Serial visual fields of the left eye. Visual field of the left eye at ( from top down) the initial presentation, and after 1, 
2, 4, and 8 months showing superior and inferior arcuate defects, which remained relatively stable and permanent through-
out the clinical course. 
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Figure 4: Retinal nerve fiber layer (RNFL) thickness progression analysis of the right eye using Zeiss Cirrus optical coherence 
tomography. Retinal nerve fiber layer thickness progression analysis from (left to right) the initial visit and after 1, 2, 4, 6 and 8 
months showing stable superior retinal nerve fiber layer thickness, but progressive inferior thinning over the clinical course.
DISCUSSION
Amiodarone is a widely used and efficacious cardiac anti-arrhythmic benzofuran derivative3-5 that can result in tox-
icity to several organs including the eyes, liver, lungs, nervous system, thyroid and skin.6-8 Many amiodarone users 
experience side effects,9 around 15% by 1 year and 50% by 5 years,10 nearly 20% of which are serious or significant 
and may necessitate discontinuation.11
Ocular involvement is typically isolated to corneal micro-deposits (verticillata), which are a well-established, dose-
dependent amiodarone-induced keratopathy seen in 70-100% of amiodarone users.3 These are benign, but in some 
cases can cause halo vision, glare or photosensitivity.5,9 Opacities in the anterior subcapsular lens may also form.12 
These both generally occur 6.5 weeks or later after the initiation of amiodarone,5 are non-threatening and gener-
ally not bothersome to patients. Corneal verticillata are due to amiodarone-induced lipodosis.8 Amiodarone is very 
lipophilic and can similarly deposit into tissues throughout the body,8,13 slow nerve conduction velocity,8 and lead to 
other documented secondary problems systemically. 4,8,13 Amiodarone-associated optic neuropathy was first identi-
fied in 1987 and can cause visual devastation, including permanent vision loss.1,2,5,12-19 The pathophysiology of its 
development is not yet fully established; however, ischemia secondary to mechanical or biochemical hindering of 
axoplasmic flow due to the accumulation of intracytoplasmic lamellar inclusion bodies, a drug-induced lipidosis,4 
particularly in large optic nerve axons, has been implicated.20 
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Figure 5: Retinal nerve fiber layer (RNFL) thickness progression analysis of the left eye using Zeiss Cirrus optical coherence 
tomography. Retinal nerve fiber layer thickness progression analysis from (left to right) the initial visit and after 1, 2, 4, 6 and 
8 months showing retinal nerve fiber layer thinning in all quadrants over the clinical course. 
Even though corneal verticillata is the most common ocular sequelae of amiodarone use, and this patient did not ex-
hibit verticillata, its absence does not preclude the diagnosis of amiodarone-associated optic neuropathy. In support 
of this statement, Johnson et al presented a case series and review and found that amiodarone-associated optic neu-
ropathy developed within six months of initiating amiodarone therapy for 19 of 35 (54%) patients who had amiodarone 
keratopathy and 13 of 18 (72%) of patients without amiodarone keratopathy. The authors further stated, “Consequent-
ly, patients with amiodarone-associated optic neuropathy may not exhibit corneal verticillate, particularly since the 
median duration of amiodarone use in patients with vision loss is four months. Hence, absence of amiodarone kera-
topathy should not dissuade clinicians from establishing the diagnosis of amiodarone-associated optic neuropathy.”21
Reported cases and cumulative reviews of amiodarone-associated optic neuropathy indicate that it generally 
occurs simultaneously bilaterally (around 66%)2,22 and most often shows an insidious onset with slowly pro-
gressive visual symptoms over months,2,18,22,23 associated with optic disc edema and subsequent atrophy.2,23,24 
Nearly 90% of those affected develop clinical manifestations of optic neuropathy within 12 months,18 with 
symptoms of vision loss occurring at a mean of 9 months and a median of about 3-4 months after drug initia-
tion;2,18,25 however, optic neuropathy has been reported as early as 3-4 weeks after intravenous or oral amio-
darone administration.13,14 Acuity at presentation may range from 20/15 to light perception, with nearly 20% 
having acuity of 20/200 or worse.2,18 While it may present with acute vision loss, 13% to nearly 30% of patients 
may be asymptomatic, even with clinically evident optic neuropathy. 2,18 Visual field deficits vary, but tend to 
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be relatively mild and may include centrocecal scotomas, mild peripheral defects, generalized constriction or 
altitudinal defects.8,18,24 This characterization of insidious onset with slow, bilateral progression and prolonged 
optic disc edema progressing to atrophy was first described by Macaluso et al., and later echoed by subsequent 
reports, case series and reviews.8,17,22,23 However, cases may deviate from this generalization and can present 
with acute vision loss or unilateral optic neuropathy.18 Stabilization of the optic disc with resolution of edema 
tends not to occur for several months, with a median 3 months,2,18,23 even after the revocation of amiodarone. 
Interestingly, the development of optic disc edema has been reported even weeks after the discontinuation of 
amiodarone.18 Amiodarone in the blood may remain at therapeutic or near-therapeutic levels for extended pe-
riods due to its variable and long half-life,18,26 averaging 58 but up to 142 days,27 and thus is thought to continue 
to exert a toxic effect on the disc even after drug discontinuation.14,28
Table 1: Retinal nerve fiber layer average thickness (μm) in each quadrant in the right and left eyes at initial presentation 
and 1, 2, 2.5, 4, 6 and 8 months from the initial presentation, and final variance in retinal nerve fiber layer thickness (μm) 
from the initial evaluation at 8 months. 
Retinal Nerve Fiber Layer Thickness Progression
Interval from 
Presentation
Right Eye Left Eye
Inferior Superior Nasal Temporal Inferior Superior Nasal Temporal
0 105 63 63 50 215 117 134 150
1 month 107 65 62 44 159 97 149 87
2 months 98 59 60 39 134 61 100 62
2.5 months 98 63 66 36 107 81 69 72
4 months 97 56 61 46 108 67 72 64
6 months 91 59 60 35 77 52 66 49
8 months 89 59 63 37 70 49 60 45
Final Variance 
From Initial 
Presentation
-16 -4 0 -13 -145 -68 -74 -105
Table 2: Visual field mean deviation (dB) and pattern standard deviation (dB) in the right and left eyes at initial presentation and 
1, 2, 4 and 8 months from initial presentation, which ultimately remained relatively stable in both eyes over the clinical course. 
Visual Field Mean Deviation and Pattern Standard Deviation Progression
Interval from  
Presentation
Right Eye 
Mean Deviation
Right Eye Pattern 
Standard Deviation
Left Eye 
Mean Deviation
Left Eye Pattern  
Standard Deviation
0 -5.58 3.82 -7.62 5.61
1 month -8.38 5.64 -6.36 2.97
2 months -7.22 3.97 -7.66 4.74
4 months -6.28 6.28 -7.33 6.69
8 months -5.47 3.81 -8.78 6.75
The prognosis varies from some improvement in up to 40-58% of patients, a decline in acuity in 10-21%, even after amio-
darone discontinuation, and permanent visual loss that remains stable compared to presentation in 21%.2,18 Acuity worse 
than 20/200 in at least one eye has been shown in 20% of those affected.2 Visual field loss is generally permanent.18 Similar 
to this case, previous reports have documented a transient increase in retinal nerve fiber layer thickness consistent with 
acute optic disc edema, followed by progressive axonal loss, as measured by optical coherence tomography, even after the 
discontinuation of amiodarone.15 This axonal loss is appreciated clinically as pallor of the optic disc.14,18,24 
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There remains some controversy as to whether amiodarone-associated optic neuropathy is truly an entity distinct 
from non-arteritic anterior ischemic optic neuropathy, typically its main differential diagnosis,8,14 if it is simply a 
variant, or possibly only a risk factor for it.4,29 Non-arteritic anterior ischemic optic neuropathy is thought to be 
due to ischemia involving the posterior ciliary arteries.30 Non-arteritic anterior ischemic optic neuropathy and 
amiodarone-associated optic neuropathy patients share similar systemic cardiovascular risk factors,31 along with 
similar clinical characteristics such as the appearance of the optic discs and patterns of visual field loss,19,23 making 
the differentiation more difficult.32,33 However, there are features of amiodarone-associated optic neuropathy that 
are atypical of non-arteritic anterior ischemic optic neuropathy, and growing clinical evidence supports that it is a 
distinct diagnosis.8,34 
Unlike amiodarone-associated optic neuropathy, non-arteritic anterior ischemic optic neuropathy generally pres-
ents acutely (over hours to days, possibly weeks)2,31 with severe,35 unilateral optic nerve dysfunction,31 typically in-
ferior altitudinal visual field defects,31,35-37 and acuity ranging from 20/20 to no light perception.38 The resolution of 
disc edema typically occurs over the course of 4-8 weeks.14,23 The incidence in those over 50 years of age has been 
reported to be 0.01-0.02%,35,39 which is much lower than that reported for amiodarone-associated optic neuropathy. 
Cases may be bilateral, but are almost universally sequential rather than simultaneous.40 Bilateral cases present at a 
lower rate than that seen in amiodarone-associated optic neuropathy,14 as simultaneously bilateral cases are usually 
associated with sudden arterial hypotension or perioperative hypovolemia.41,42 
Most (90%) cases of amiodarone-associated optic neuropathy have been reported in males,18 while non-arteritic 
anterior ischemic optic neuropathy exhibits an equal male-female distribution.2,39 Cheng et al. conducted a retro-
spective population-based cohort study to investigate whether there was an increased risk of optic neuropathy in 
amiodarone-treated patients, and found a 2-fold increased risk; male amiodarone users had a 3-fold greater risk 
of optic neuropathy.34 Amiodarone-associated optic neuropathy has no predilection for small discs or cup-to-disc 
ratios,18 whereas non-arteritic anterior ischemic optic neuropathy has a nearly exclusive predilection for small optic 
discs with small cup-to-disc ratios.43 
Performance on color vision testing may vary depending on the optic nerve’s function in any optic neuropathy,37 but 
tends to remain normal in ischemic, but abnormal in inflammatory, optic neuropathies.36 Miller and Arnold report 
that loss of color vision in non-arteritic anterior ischemic optic neuropathy tends to parallel that of acuity.31 Blue 
color deficiency has been reported as an early indication of amiodarone-associated optic neuropathy;44 thus, color 
testing may be a helpful tool for assessment and monitoring. In this patient, abnormal color testing results were not 
used as a functional measure for disease-monitoring because he reported congenital color deficiency with unknown 
baseline color-discrimination ability. 
The direct cause of optic neuropathy due to amiodarone use has not been well established, and thus is not uni-
versally accepted. Regarding ocular toxicology, Fraunfelder and Shults assert that there are inadequate data to 
support amiodarone as a cause of toxic optic neuropathy,29 and Younge aptly notes that causation cannot be con-
firmed without a prospective controlled study, which would be difficult to design.45 There are ethical limitations 
to conducting an ideal prospective, double-masked, randomized, placebo-controlled study, because this would 
require the withholding of treatment in the placebo control group; however, since amiodarone is used to treat 
life-threatening cardiac dysrhythmias, withholding treatment would be unethical.8 Similarly, positive re-chal-
lenge of the drug in cases of optic neuropathy to confirm its causation would also be unethical. Thus, causation 
remains only strongly speculated. 
Mindel et al. undertook a randomized trial investigating amiodarone’s role in the prevention of sudden cardiac 
death, and bilateral vision loss was considered a secondary end-point as a way to explore this entity. Of the 
837 subjects using amiodarone, none self-reported bilateral vision loss.25 However, patients did not undergo 
ophthalmic examinations, and this endpoint was reached if subjects reported “yes” to having “optic neuritis.”25 
Therefore, mild, unilateral, peripherally affected, or asymptomatic cases may have gone undetected, and pa-
tients may have underreported their visual symptoms due to poor understanding of the investigator’s inquiry 
regarding “optic neuritis.” 
In the present case, the patient remained visually asymptomatic in the left eye. He presented with symptomatic 
arcuate inferior visual field loss in the right eye, which could have represented superior optic nerve segment non-
arteritic anterior ischemic optic neuropathy prior to the development of, or in conjunction with, amiodarone-asso-
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ciated optic neuropathy; however, it is unlikely that the subsequent optic disc swelling in the right eye represented 
a sequential unilateral non-arteritic anterior ischemic optic neuropathy. Subsequent non-arteritic anterior ischemic 
optic neuropathy in the fellow eye was found to occur in 14.7% of cases by 5 years in a ischemic optic neuropathy de-
compression trial;46 however, subsequent non-arteritic anterior ischemic optic neuropathy in the same eye is much 
less common, reportedly only up to 6.4%.47 Given that optic disc crowding is a risk factor, the low risk of sequential 
ipsilateral disease is presumably associated with decompression of the disc as the affected fibers atrophy, though 
other factors also likely contribute.48 This patient’s baseline cup-to-disc ratio was unknown, thus the association 
of non-arteritic anterior ischemic optic neuropathy to small cup-to-disc ratios cannot be confidently applied or 
excluded; regardless, there is only a very small likelihood of a sequential non-arteritic anterior ischemic optic neu-
ropathy in the same eye in association with sequential or simultaneous visually asymptomatic non-arteritic anterior 
ischemic optic neuropathy in the fellow eye in this patient. However, it remains possible that the patient had supe-
rior segmental non-arteritic anterior ischemic optic neuropathy in his right eye previous to, or co-existing with, the 
bilateral amiodarone-associated optic neuropathy. 
Amiodarone-associated optic neuropathy remains a clinical diagnosis of exclusion, but should be a differential di-
agnosis with optic neuropathy surrounding use of the drug. Other differential diagnoses include papilledema and 
other optic neuropathies such as those associated with infectious, inflammatory, infiltrative, compressive, nutri-
tional, metabolic or other toxic sources.5 This patient had a lack of pertinent exposures to various infectious causes 
such as tuberculosis, syphilis, Lyme disease or cat scratch disease, and, in conjunction with his clinical presentation, 
infectious etiologies were thought unlikely. Further laboratory investigations aside from a rapid plasma reagin to 
screen for syphilis were not pursued. which represents a limitation of this report. 
In cases of bilateral optic disc edema, giant cell arteritis and increased intracranial pressure must be excluded.22 
This patient initially had a mildly elevated C-reactive protein and erythrocyte sedimentation rate; both can be 
elevated in giant cell arteritis and numerous other conditions.49 The American College of Rheumatology’s diag-
nostic criteria for giant cell arteritis include an erythrocyte sedimentation rate of 50 mm/hour or more.50 Hayreh 
et al. reported that the “(c)linical criteria most strongly suggestive of giant cell arteritis include jaw claudication, 
C-reactive protein above 2.45 mg/dl, neck pain, and an erythrocyte sedimentation rate of 47 mm/hour or more, 
in that order”, and this patient demonstrated none of these.49 Also, his platelet count was normal. A platelet count 
greater than 400 x103/μL has been reported as a useful marker to predict that a temporal artery biopsy would be 
positive for giant cell arteritis,51 and thrombocytosis has been reported to be a predictor of an ultimate diagnosis 
of giant cell arteritis in patients referred for temporal artery biopsies;52 this patient’s platelet count was well be-
low that threshold. Additionally, he denied systemic symptoms typical of giant cell arteritis, and though it may 
be isolated without systemic symptoms despite a confirmed positive temporal artery biopsy in some cases,53 his 
central visual acuity was well-preserved in both eyes, which is not consistent with arteritic anterior ischemic 
optic neuropathy. Additionally, the duration of disc edema without substantial vision loss is not consistent with 
arteritic ischemic optic neuropathy. These several factors lead to a very low level of suspicion, so temporal artery 
biopsy was not warranted or pursued. 
Papilledema due to increased intracranial pressure was also considered. This patient underwent neuroimaging that 
ruled out a mass lesion, and the radiologist detected no secondary radiologic evidence of increased intracranial 
pressure or dural venous sinus thrombosis, such as optic nerve sheath enlargement,54 flattening of the posterior 
sclera,55 or optic nerve tortuosity.54,56 Because of the patient’s anti-coagulated state and the low suspicion of in-
creased intracranial pressure, a lumbar puncture was deferred. 
CONCLUSIONS
In this patient, his retinal nerve fiber layer thickness remained roughly stable superiorly and nasally in his right 
eye over the duration of the clinical course, but already appeared pale at the time of presentation. The inferior 
and temporal retinal nerve fiber layer thickness dropped by 16 and 13 μm, respectively, as the inferior edema pro-
gressed to become somewhat atrophic. His left eye, which upon initial evaluation had gross optic disc edema, had 
dramatic relative retinal nerve fiber layer thinning over the clinical course, more blatantly inferiorly (-145 μm), then 
temporally (-105 μm), nasally (-74 μm) and lastly superiorly (-68 μm). FitzGibbon and Taylor reported that, in hu-
man retinas, retinal ganglion cell axons tend to be larger on average inferiorly and/or nasally than superiorly and/
or temporally, and that foveal axons are generally smaller than extrafoveal axons.57 Interestingly, this case demon-
strated more retinal nerve fiber layer loss inferiorly in both eyes, suggesting that the generally larger inferior axons 
were more significantly affected by this optic neuropathy. In conjunction with Mansour’s findings suggesting that 
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amiodarone use results in the accumulation of intracytoplasmic lamellar inclusion bodies, particularly in large op-
tic nerve axons, FitzGibbon and Taylor’s finding of a variable retinal axonal size distribution may be significant for 
future investigations of amiodarone-associated optic neuropathy’s relative regional optic nerve impact and involve-
ment based on axonal diameter. 
Though uncommon, amiodarone use can lead to optic neuropathy, which can cause a permanent loss of visual 
acuity or field. Symptoms are usually insidious and patients may even be asymptomatic, so detection of optic neu-
ropathy, prior to the development of visual symptoms, would be ideal; color vision testing, a dilated exam and visual 
fields have great clinical utility in early detection. It is advised that patients be evaluated with a comprehensive eye 
examination at 4 and 12 months after initiating amiodarone therapy,18 and at least annually thereafter.5,18 
Aside from early detection, it can be difficult to decide upon the appropriate course of action in cases of amioda-
rone-associated optic neuropathy, particularly in patients who are visually asymptomatic. There is no unanimity 
regarding whether amiodarone should be discontinued, because there can be varying visual outcomes regardless 
of whether amiodarone is discontinued, and clearly these patients need to treat their high-risk underlying arrhyth-
mia.4 Patient care should be individualized, and consultation with the patient’s cardiologist is needed to carefully 
consider the risks and benefits of amiodarone therapy. l
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